Advertisement
Canada markets open in 8 hours 51 minutes
  • S&P/TSX

    22,116.69
    -152.41 (-0.68%)
     
  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     
  • DOW

    38,571.03
    -115.27 (-0.30%)
     
  • CAD/USD

    0.7334
    -0.0006 (-0.08%)
     
  • CRUDE OIL

    73.53
    -0.69 (-0.93%)
     
  • Bitcoin CAD

    94,428.39
    +1,138.84 (+1.22%)
     
  • CMC Crypto 200

    1,448.77
    -19.17 (-1.31%)
     
  • GOLD FUTURES

    2,368.90
    -0.40 (-0.02%)
     
  • RUSSELL 2000

    2,059.68
    -10.45 (-0.50%)
     
  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     
  • NASDAQ futures

    18,656.00
    +9.75 (+0.05%)
     
  • VOLATILITY

    13.11
    +0.19 (+1.47%)
     
  • FTSE

    8,262.75
    -12.63 (-0.15%)
     
  • NIKKEI 225

    38,892.31
    -30.69 (-0.08%)
     
  • CAD/EUR

    0.6720
    -0.0007 (-0.10%)
     

Struggling 23andMe Granted Extension to Revive Stock Price

(Bloomberg) -- Embattled DNA-testing firm 23andMe Holding Co. has been granted an additional 180 days to move its shares above $1 and avoid being delisted, according to a filing with the Securities and Exchange Commission.

Most Read from Bloomberg

The stock has traded below the $1 Nasdaq minimum since late last year, with the clock is ticking to regain compliance. It will now have until Nov. 4 to regain compliance.

ADVERTISEMENT

23andMe agreed to go public in 2021 via a merger with a special purpose acquisition company founded by billionaire Virgin Group founder Richard Branson. It was valued at $3.5 billion at the time. In just a few years, the stock has lost more than 90% of its value as the consumer DNA testing revolution the company sought has been slow to catch on.

The company didn’t immediately respond to a request for comment.

Last month, Chief Executive Officer Anne Wojcicki said she’s considering taking the company private, telling board members she is proposing to acquire the company, according to a filing. In February, she told Bloomberg she was considering several strategies to revive the stock price, among them splitting the company’s drug-development business from its consumer spit kit business.

Most Read from Bloomberg Businessweek

©2024 Bloomberg L.P.